TSXV: DVA
TORONTO, April 26, 2018 /CNW/ - Delivra Corp. ("Delivra",
or "the Company") today announced that its R&D, pre-clinical
and clinical teams have successfully developed and tested
line-extension products using its precision topical delivery system
platform, DelivraTM. These consumer product initiatives
include cannabis-related products at both the over-the-counter
("OTC") and prescription levels. With the assistance and support of
Emergence, Canada's virtual
incubator that supports the growth of innovative bioscience and
food sector ventures, Delivra has developed its strategy and
executed on ready to use products for OTC line extensions that will
compliment its already existing successful LivRelief products, and
is ready for the upcoming legalization of cannabis with its vast
array of cannabis-related products for third party distributors for
different disease indications.
Overall, the evaluation strategies affirms that Delivra's novel
proprietary delivery system can achieve further gains within the
chronic pain and sleep/anxiety markets. Importantly, current sales
and gross margins outperform several competing brand names in the
pain segment and an acceleration of LivRelief's successful suite of
products is expected to be met with success. This acceleration of
LivRelief sales growth in the topical OTC category will involve
additional unique SKUs at existing accounts and an enhancement of
the distribution channels, which is now over 5,200 pharmacy/grocery
and natural products stores.
"Delivra will continue to implement a strategy to develop a
multi-formulation/multi-size portfolio, while maintaining and
strengthening its fundamental natural brand position through
scientific and natural ingredient synergies, while continuing to
increase our presence at the prescription level. As part of our
newest marketing initiative, we will focus on further increasing
brand awareness, bolster marketing and distribution efforts and
providing innovative packaging of our currently successful suite of
consumer products. Driving increased sales with a proprietary suite
of innovative products remains one of our key focuses. This
reaffirms our commitment to further develop and commercialize our
expanding pipeline of cream-based therapeutics across Canada and we thank Emergence for their
ongoing support of Delivra and its vision," said Dr. Joseph Gabriele, CEO of Delivra.
ABOUT DELIVRA CORP.
Delivra Corp. is a specialty biotechnology company having a
proprietary transdermal delivery system platform that can shuttle
pharmaceutical and natural molecules through the skin, in a
targeted manner. Delivra manufactures and sells a growing line of
natural topical creams with the proprietary transdermal delivery
system platform under the LivReliefTM brand, for
conditions such as joint and muscle pain, nerve pain, varicose
veins, wound healing, and under the LivSportTM brand for
sports performance. LivReliefTM products are available
in pharmacies, grocery chains, and independent health food stores
across Canada, including, but not
limited to, Shoppers Drug Mart, Walmart, Loblaw, Rexall,
Pharmasave, London Drugs, and on-line at www.livrelief.com. In
parallel with its consumer products business, Delivra also has a
mandate to license its patent-pending, proprietary transdermal
delivery technology platform to pharmaceutical companies globally,
for the repurposing of pharmaceutical molecules transdermally to
treat a broad range of conditions, along with licensing its
over-the-counter products globally. Delivra is headquartered in
Hamilton, Ontario and has a
research and development laboratory in Charlottetown, PEI.
Further information on Delivra can be found at
www.delivracorp.com and www.livrelief.com.
ABOUT EMERGENCE
Emergence is a virtual incubator that supports the formation and
growth of innovative bioscience and food sector ventures. Emergence
clients benefit from access to business, technical, scientific and
regulatory support services customized to meet their individual
needs. This includes one-on-one and team-based mentorship;
third-party consulting services; market research; legal, IP,
insurance, tax and financial expertise from a network of
professional service provider partners; and support accessing
international networks and public and private funding and
investment opportunities. As a virtual incubator Emergence serves
high-potential companies wherever they are located in Canada; while also providing a "soft landing"
for innovative international bioscience ventures seeking to
start-up or establish themselves in, or expand into, Canada.
Further information on Emergence can be found at
https://emergencebioincubator.com/
Cautionary Note Regarding Forward-Looking Statements
This news release includes certain information and statements
about management's view of future events, expectations, plans and
prospects that constitute "forward-looking statements", which are
not comprised of historical facts. Forward-looking statements may
be identified by such terms as "believes", "anticipates",
"intends", "expects", "estimates", "may", "could", "would", "will",
or "plan", and similar expressions. Specifically, forward-looking
statements in this news release include, without limitation,
statements regarding: the Company's revenues and financial
performance; the Company's drug research and development plans; the
timing of operations; and estimates of market conditions. These
statements involve known and unknown risks, uncertainties, and
other factors that may cause actual results or events, performance,
or achievements of Delivra to differ materially from those
anticipated or implied in such forward-looking statements. The
Company believes that the expectations reflected in these
forward-looking statements are reasonable, but there can be no
assurance that actual results will meet management's expectations.
In formulating the forward-looking statements contained herein,
management has assumed that business and economic conditions
affecting Delivra will continue substantially in the ordinary
course and will be favourable to Delivra; that the Company will
continue to complete orders with existing customers and control
product pricing and expenses that clinical testing results will
justify commercialization of the Company's drug candidates; that
Delivra will be able to obtain all requisite regulatory approvals
to commercialize its drug candidates, that such approvals will be
received on a timely basis, and that Delivra will be able to find
suitable partners for development and commercialization of its
products and intellectual property on favourable terms. Although
these assumptions were considered reasonable by management at the
time of preparation, they may prove to be incorrect. Factors that
may cause actual results to differ materially from those
anticipated by these forward-looking statements include: the
ability of the Company to maintain existing product sales with
current customers at existing product pricing and expenses;
uncertainties associated with obtaining regulatory approval to
perform clinical trials and market products; the need to establish
additional corporate collaborations, distribution or licensing
arrangements; the ability of the Company to generate sales and
profits; the Company's ability to raise additional capital if and
when necessary; intellectual property disputes; increased
competition from pharmaceutical and biotechnology companies;
changes in equity markets, inflation, and changes in exchange
rates; and other factors as described in detail in Delivra's public
filings, all of which may be viewed on SEDAR (www.sedar.com). Given
these risks and uncertainties, readers are cautioned not to place
undue reliance on such forward-looking statements and information,
which are qualified in their entirety by this cautionary statement.
Except as required by law, Delivra disclaims any intention and
assumes no obligation to update or revise any forward-looking
statements to reflect actual results, whether as a result of new
information, future events, changes in assumptions, changes in
factors affecting such forward-looking statements or otherwise.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
SOURCE Delivra Corp